Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
30.33
-0.10 (-0.33%)
May 6, 2025, 9:32 AM EDT - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Chronic Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chronic Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kidney Care | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kidney Care Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Infusion Therapies | 4.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Infusion Therapies Growth | 3.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery | 1.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery Growth | 5.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies | 5.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies Growth | 3.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals | 2.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Growth | 7.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Care & Connectivity Solutions | 1.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Care & Connectivity Solutions Growth | 0.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care | 1.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care Growth | -6.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies | 2.95B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Growth | -2.06% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia | 1.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia Growth | 1.93% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding | 1.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding Growth | 15.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) | 67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) Growth | -22.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Medical Products & Therapies Operating Income | 950.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies Operating Income Growth | -2.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income | 468.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income Growth | -3.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income | 313.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income Growth | -21.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kidney Care Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income | 18.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth | 0% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| United States Revenue | 5.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Revenue Growth | 1.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue | 1.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Revenue Growth | 0.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue | 3.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue Growth | 5.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|